Main Subjects = Medicinal chemistry and drug design
Number of Articles: 13
PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Volume 68, Issue 2, September 2023, Pages 64-81

Mohamed Ayman ALy El-Zahabi; Reda G Yousef; Ibrahim H Eissa; Alaa Elwan

EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Volume 68, Issue 2, September 2023, Pages 82-110

Abdelsalam Mohamed Ouf; Adel A Marzouk; Montaser A Shykhoon; Mohamed Ayman ALy El-Zahabi

VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS

Volume 68, Issue 2, September 2023, Pages 111-129

Helmy Sakr; Islam Otify; Rezk R Ayyad; Alaa Elwan

AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS

Volume 68, Issue 2, September 2023, Pages 130-158

Mostafa Mohammed Aref; Abeer A Mohamed; Mohammed A Dahab; Mohamed Ayman ALy El-Zahabi

REVIEW ON THE SIGNIFICANCE OF PYRIMIDINE DERIVATIVES AS POTENT ANTI-ANGIOGENIC VEGFR-2 INHIBITORS

Volume 67, Issue 1, March and April 2023, Pages 37-50

ibrahim issa; Abdulrahman Saleh; Mohamed Khalifa; Hazem Mahdy

RECENT ADVANCES ON PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS.

Volume 67, Issue 1, March and April 2023, Pages 51-67

Hazem Mahdy; Hany Elnagar; Helmy Sakr

PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS

Volume 67, Issue 1, March and April 2023, Pages 68-83

ibrahim issa; Ahmed Hammam; Helmy Sakr; Rezk Ayyad

RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY.

Volume 66, Issue 2, September and October 2022, Pages 56-86

Hazem Mahdy; Mahmoud Shaat; rezk Ayyad

Al-Azhar Journal of Pharmaceutical Sciences

Journal Archive